ABSORPTION, DISTRIBUTION AND EXCRETION OF NITROFURAN COMPOUNDS

Absorption, distribution and excretion of four nitrofuran compounds were studied in rats, using14C-labeled materials. (1) When 10 mg/kg of these nitrofuran compounds were administered orally to rats, expected absorption percentage were as follows, 1, 5-bis (5-nitro-2-furyl) -1, 4-pentadiene-3-one am...

Full description

Saved in:
Bibliographic Details
Published in:CHEMOTHERAPY Vol. 22; no. 7; pp. 1165 - 1170
Main Authors: TAKAI, AKIRA, NAKASHIMA, YOSHIFUMI, SIMIZU, ETSURO, TERASHIMA, NOBUO
Format: Journal Article
Language:English
Japanese
Published: Japanese Society of Chemotherapy 1974
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Absorption, distribution and excretion of four nitrofuran compounds were studied in rats, using14C-labeled materials. (1) When 10 mg/kg of these nitrofuran compounds were administered orally to rats, expected absorption percentage were as follows, 1, 5-bis (5-nitro-2-furyl) -1, 4-pentadiene-3-one amidinohydrazone hydrochloride (PZ) : 2-4%, 3-amino-6- (2- (5-nitro-2-furyl) vinyl) -1, 2, 4-triazine (FT-H) and 3-di (hydroxymethyl) amino-6- (2- (5-nitro-2-furyl) vinyl) -1, 2, 4-triazine (FT) : 40-50%, and 3-acetamido-6- (2- (5-nitro-2-furyl) vinyl) -1, 2, 4-triazine (FT-Ac) : about 20%. (2) The plasma level of radioactivity reached maximum within 1 hour for14C-FT-H or 2 hours for14C-FT and 14C-FT-Ac after oral administration, and then disappeared rapidly. (3) The distribution of 14C-labeled nitrofuran compounds in rats tissues showed comparativery higher levels in kidney, liver, bladder, stomach and intestine, and lower in pancreas, spleen, adrenal, heart, lung, testis, fat, muscle, brain and eye ball, and most of them were found to be practically negligible at 24 hours after oral administration. (4) Excretion studies showed that the radioactivity of these14C-labeled nitrofuran compounds were excreted completely within 120 hours after oral administration.
ISSN:0009-3165
1884-5894
DOI:10.11250/chemotherapy1953.22.1165